Jacobs Levy Equity Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Jacobs Levy Equity Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.21M	Sell	42,726 -83,491	-66%	-$4.25M	0.01%	568
2025 Q4	$6.27M	Buy	126,217 +87,044	+222%	+$4.23M	0.02%	365
2025 Q3	$1.87M	Buy	+39,173	New	+$1.58M	0.01%	606
2021 Q1	–	Sell	-683,835	Closed	-$17.2M	–	1112
2020 Q4	$17.2M	Buy	683,835 +136,537	+25%	+$2.94M	0.15%	165
2020 Q3	$11.4M	Buy	547,298 +90,717	+20%	+$2.06M	0.12%	192
2020 Q2	$10.8M	Buy	456,581 +404,362	+774%	+$8.93M	0.12%	202
2020 Q1	$939K	Buy	+52,219	New	+$1.1M	0.01%	640
2018 Q2	–	Sell	-12,710	Closed	-$582K	–	1100
2018 Q1	$582K	Buy	+12,710	New	+$530K	0.01%	753
2015 Q2	–	Sell	-15,600	Closed	-$189K	–	859
2015 Q1	$189K	Buy	+15,600	New	+$147K	﹤0.01%	709

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's SUPN Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its Supernus Pharmaceuticals (SUPN) stake by 66% in Q1 2026, selling an estimated $4.25M and leaving 42,726 shares worth $2.21M. The position accounts for 0.01% of the portfolio, ranked #568.

Jacobs Levy Equity Management first reported a position in SUPN in Q1 2015 and has held it in 9 quarters since. The position peaked at $17.2M in Q4 2020. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Jacobs Levy Equity Management held 42,726 shares of Supernus Pharmaceuticals worth $2.21M as of Q1 2026.
Jacobs Levy Equity Management sold 83,491 Supernus Pharmaceuticals shares in Q1 2026, an estimated $4.25M.
Supernus Pharmaceuticals made up 0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #568 holding.
Jacobs Levy Equity Management first reported a position in Supernus Pharmaceuticals in Q1 2015 and has held it in 9 quarters since.
Jacobs Levy Equity Management's Supernus Pharmaceuticals position peaked at $17.2M in Q4 2020.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.